A trial can produce an unsuccessful primary result alongside observations worth investigating. The task is to preserve both, without promoting a secondary finding into the answer to the original question.
What was the trial designed to test?
Elkashef and colleagues’ historical eight-center, double-blind trial randomized 140 adults with methamphetamine dependence to oral topiramate or placebo for 13 weeks: 69 and 71 participants, respectively. Treatment started at 25 mg/day and targeted 200 mg/day during weeks 6–12, followed by tapering. Both groups received brief behavioral support.
The primary abstinence comparison during weeks 6–12 was not significant (p=0.13). A secondary analysis found at least a 25% reduction in median urine methamphetamine concentration in 64.2% of topiramate recipients versus 42.3% of placebo recipients (p=0.03). A subgroup of 26 participants with negative baseline urine also favored topiramate on abstinence. Retention and achievement of the target dose were limited; pill counts measured adherence.
Why the outcome hierarchy matters
The corrected PubMed abstract specifies the 25-mg starting dose; the archived abstract contains 50 mg, while the full methods also specify 25 mg. Preserving that correction avoids repeating an error in the treatment description.
The primary result asks whether assignment to the tested regimen improved the specified abstinence outcome in the trial population. A subgroup selected by baseline urine status asks a narrower question. A positive answer to the narrower question does not retroactively change the overall result, and a subgroup of 26 is not an independent replication.
Baseline urine status also should not be translated into a verified long history of abstinence. The classification describes evidence available at entry. A single negative result and a sustained pattern of abstinence are different observations.
Does lower urine concentration mean a known reduction in dose?
A concentration-based outcome and a count of days without use are not interchangeable. The units of measurement should remain visible: a urine result expresses analyte in a specimen, whereas a consumed dose expresses an amount administered. Calling the former a measured dose reduction would require an additional validated relationship.
In evaluating the paper, an expert should therefore identify which outcome supports each sentence. The primary abstinence analysis, the quantitative urine analysis and the baseline-negative subgroup belong in separate parts of the explanation. Doing so preserves a possible research signal while keeping the main null result visible.
These data can motivate a more focused trial. They do not establish a current prescribing recommendation, nor do they show that every person who begins treatment with a negative test will benefit.
Source
Elkashef A, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012;107:1297–1306. doi:10.1111/j.1360-0443.2011.03771.x. Full text; corrected bibliographic abstract.